The prognostic value of the preoperative lung immune prognostic index in patients with urothelial bladder cancer undergoing radical cystectomy.
Bladder cancer
Inverse probability of treatment weighting
Lung immune prognostic index
Radical cystectomy
dNLR
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
10
06
2021
accepted:
20
10
2021
pubmed:
30
10
2021
medline:
9
2
2022
entrez:
29
10
2021
Statut:
ppublish
Résumé
The lung immune prognostic index (LIPI) predicts the prognosis of patients with advanced non-small-cell lung cancer and is a prognostic biomarker for renal cell carcinoma and melanoma; however, no study has evaluated its potential as a preoperative biomarker for patients with bladder cancer (BC). We investigated the LIPI as a preoperative prognostic biomarker in patients undergoing radical cystectomy. We retrospectively analyzed the clinical records of 105 patients with BC who underwent radical cystectomy from January 2013 to June 2019. The LIPI was evaluated based on the preoperatively derived neutrophil-lymphocyte ratio and the lactate dehydrogenase levels. Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier curves and decision curve analysis (DCA) were performed to assess the disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) rates. The patients were classified into the good, intermediate, and poor LIPI groups [71 (67.6%), 28 (26.7%), and 6 (5.7%) patients, respectively]. IPTW-adjusted Kaplan-Meier curve analyses showed that patients with intermediate to poor LIPI had worse DFS, CSS, and OS rates than those with good LIPI. The LIPI combined with pT3/4 and lymph node metastasis could better assess the prognosis of DFS at 24 months postoperatively by DCA. The preoperative LIPI can predict the prognosis of patients with BC undergoing radical cystectomy and has a better predictive ability when combined with pT3/4 and lymph node metastasis.
Sections du résumé
BACKGROUND
BACKGROUND
The lung immune prognostic index (LIPI) predicts the prognosis of patients with advanced non-small-cell lung cancer and is a prognostic biomarker for renal cell carcinoma and melanoma; however, no study has evaluated its potential as a preoperative biomarker for patients with bladder cancer (BC). We investigated the LIPI as a preoperative prognostic biomarker in patients undergoing radical cystectomy.
METHODS
METHODS
We retrospectively analyzed the clinical records of 105 patients with BC who underwent radical cystectomy from January 2013 to June 2019. The LIPI was evaluated based on the preoperatively derived neutrophil-lymphocyte ratio and the lactate dehydrogenase levels. Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier curves and decision curve analysis (DCA) were performed to assess the disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) rates.
RESULTS
RESULTS
The patients were classified into the good, intermediate, and poor LIPI groups [71 (67.6%), 28 (26.7%), and 6 (5.7%) patients, respectively]. IPTW-adjusted Kaplan-Meier curve analyses showed that patients with intermediate to poor LIPI had worse DFS, CSS, and OS rates than those with good LIPI. The LIPI combined with pT3/4 and lymph node metastasis could better assess the prognosis of DFS at 24 months postoperatively by DCA.
CONCLUSION
CONCLUSIONS
The preoperative LIPI can predict the prognosis of patients with BC undergoing radical cystectomy and has a better predictive ability when combined with pT3/4 and lymph node metastasis.
Identifiants
pubmed: 34714458
doi: 10.1007/s10147-021-02059-8
pii: 10.1007/s10147-021-02059-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
396-402Informations de copyright
© 2021. Japan Society of Clinical Oncology.
Références
International Agency for Research on Cancer (2021) Estimated number of new cases in 2020, worldwide, both sexes, all ages. In: Cancer Today. https://gco.iarc.fr/today/online-analysis-table . Accessed Mar 2021
Dinney CPN (2006) Therapy of invasive bladder cancer. Urology 67:56–59
doi: 10.1016/j.urology.2006.01.043
Giuliani L, Giberti C, Martorana G et al (1985) Results of radical cystectomy for primary bladder cancer. retrospective study of more than 200 cases. Urology 26:243–248
doi: 10.1016/0090-4295(85)90119-0
Pagano F, Bassi P, Galetti TP et al (1991) Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 145:45–50
doi: 10.1016/S0022-5347(17)38244-7
Hermanns T, Bhindi B, Wei Y et al (2014) Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer 111:444–451
doi: 10.1038/bjc.2014.305
Rajwa P, Życzkowski M, Paradysz A et al (2018) Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. Eur Rev Med Pharmacol Sci 22:3027–3037
pubmed: 29863247
Ma JY, Hu G, Liu Q (2019) Prognostic significance of the lymphocyte-to-monocyte ratio in bladder cancer undergoing radical cystectomy: a meta-analysis of 5638 individuals. Dis Markers 2019:7593560
pubmed: 31089397
pmcid: 6476040
Wang R, Yan Y, Liu S et al (2019) Comparison of preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios in bladder cancer patients undergoing radical cystectomy. BioMed Res Int 2019:3628384
pubmed: 31662975
pmcid: 6791262
van Kessel KEM, de Haan LM, Fransen van de Putte EE et al (2016) Elevated derived neutrophil-to-lymphocyte ratio corresponds with poor outcome in patients undergoing pre-operative chemotherapy in muscle-invasive bladder cancer. Bladder Cancer 2:351–360
doi: 10.3233/BLC-160055
Miyake M, Morizawa Y, Hori S et al (2017) Integrative assessment of pretreatment inflammation-, nutrition-, and muscle-based prognostic markers in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Oncology 93:259–269
doi: 10.1159/000477405
Lee SM, Russell A, Hellawell G (2015) Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma. Korean J Urol 56:749–755
doi: 10.4111/kju.2015.56.11.749
Mezquita L, Auclin E, Ferrara R et al (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer. JAMA Oncol 4:351–357
doi: 10.1001/jamaoncol.2017.4771
Ruiz-Bañobre J, Areses-Manrique MC, Mosquera-Martínez J et al (2019) Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res 8:1078–1085
doi: 10.21037/tlcr.2019.11.07
Meyers DE, Stukalin I, Vallerand IA et al (2019) The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors. Cancers (Basel) 11:E1713
doi: 10.3390/cancers11111713
Su S, Lizhe L, Sun C et al (2020) Prognostic significance of serum lactate dehydrogenase in patients undergoing radical cystectomy for bladder cancer. Urol Oncol 38:852.e1-852
doi: 10.1016/j.urolonc.2020.05.031
Paner GP, Stadler WM, Hansel DE et al (2018) Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol 73:560–569
doi: 10.1016/j.eururo.2017.12.018
Proctor MJ, McMillan DC, Morrison DS et al (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107:695–699
doi: 10.1038/bjc.2012.292
Alfred Witjes J, Lebret T, Comperat EM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71:462–475
doi: 10.1016/j.eururo.2016.06.020
Ulich TR, del Castillo J, Keys M et al (1987) Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha- induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 139:3406–3415
pubmed: 3316383
Lord BI, Bronchud MH, Owens S et al (1989) The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86:9499–9503
doi: 10.1073/pnas.86.23.9499
Teramukai S, Kitano T, Kishida Y et al (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 45:1950–1958
doi: 10.1016/j.ejca.2009.01.023
Michaud DS (2007) Chronic inflammation and bladder cancer. Urol Oncol 25:260–268
doi: 10.1016/j.urolonc.2006.10.002
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867
doi: 10.1038/nature01322
Cedrés S, Torrejon D, Martínez A et al (2012) Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 14:864–869
doi: 10.1007/s12094-012-0872-5
Uribe-Querol E, Rosales C (2015) Neutrophils in cancer: two sides of the same coin. J Immunol Res 2015:983698
doi: 10.1155/2015/983698
McMillan DC, Crozier JE, Canna K et al (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22:881–886
doi: 10.1007/s00384-006-0259-6
Petrelli F, Cabiddu M, Coinu A et al (2015) Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol 54:961–970
doi: 10.3109/0284186X.2015.1043026
Su S, Liu L, Li C et al (2019) Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: a systematic review and meta-analysis. Int J Surg 72:146–153
doi: 10.1016/j.ijsu.2019.10.043